Abstract

BackgroundMagnetic resonance imaging (MRI) is frequently used in patients with chronic back pain (CBP) to diagnose mechanical and inflammatory diseases, including axial spondyloarthritis (axSpA). Recent data suggest sacroiliac joints (SIJ) MRI findings in axSpA may differ according to sex[1]. Whether this holds true for spinal MRI and other causes of CBP is currently unknown.ObjectivesTo analyze spinal and SIJ MRI findings in young male and female patients with CBP.MethodsThe “Strategy for a Hospital Early Referral in Patients with Axial Spondyloarthritis” (SHERPAS) is a prospective ongoing study recruiting young patients (18 to 40 years) with CBP asked to undergo an MRI of the spine by other specialists different than rheumatologists in a tertiary hospital, starting in September 2021. After inclusion, an additional MRI of the SIJ, followed by a rheumatology visit and eligible blood tests were performed. Dataset for this interim analysis was locked in October 2022. The protocol for MRI of the spine used a 1.5T scanner to acquire sagittal T1-weighted turbo spin echo (TSE) and T2- weighted TSE, both for the lateral sides of vertebral bodies, and T2-Multistack. On top of this, an MRI of the SIJ, which involved T1-TSE, T2- weighted SPAIR and short-tau inversion recovery (STIR) sequences, was performed. MRI findings were assessed according to clinical practice by one of the four musculoskeletal radiologists working in the centre, describing the presence of mechanical lesions (spondylolisthesis, spondylolysis, disc herniation, disc protrusion, facet joints abnormalities), inflammatory findings (both SIJ and spine), and SIJ structural findings. For this analysis, results were stratified by sex.ResultsAmong 152 recruited patients, 85 (55.9%) were female; mean age was 34.2 (5.3) years. Spinal MRI findings were reported in 130 (87.2%) patients, with no differences between sexes (male 90.8% vs female 84.5%, p=0.3). As shown inTable, the most frequent diagnosis in both sexes were disc protrusion, followed by disc herniation. Inflammatory spinal findings were detected only in one male patient. No differences were found for any of the spinal lesions. SIJ MRI findings were reported in 49 (33.1%) patients, being numerically more frequently observed in males than females (41.5% vs 26.5%; p=0.08). Concurrence of both structural and inflammatory lesions was more frequently in males (9.2% vs 1.2%, p<0.05), while no differences in isolate SIJ MRI findings were found between sexes. Overall, 45 (29.6%) patients presented findings both in the spine and SIJ (Figure 1).ConclusionIn young patients who are requested a spinal MRI by other specialists different than rheumatologists, spinal lesions are reported in most patients, and similarly in males and females. Remarkably, SIJ MRI findings are reported in one out of three patients in this population, being more frequently in males.Reference[1]Ulas ST, et al- OP0073 New Perspectives in Axial Spondyloarthritis – First Results of Gender-Specific Assessment of MRI Imaging Criteria. Ann Rheum Dis 2022;81:50.Table 1.Findings in magnetic resonance imagingTotalMaleFemalep-valueSpine MRIn=149n= 65n= 84Any finding130 (87.2)59 (90.8)71 (84.5)0.3Structural findings129 (86.6)58 (89.2)71 (84.5)0.3 Spondylolisthesis5 (3)3 (4.6)2 (2.4)0.6 Spondylolysis2 (1)1 (1.5)1 (1.2)1 Disc herniation34 (23)15 (23.1)19 (22.6)1 Disc protrusion64 (43)31 (47.7)33 (39.3)0.3 Facet joints abnormalities8 (5)1 (1.5)7 (8.2)0.1 Other16 (11)7 (10.8)9 (10.7)1Inflammatory findings1 (1)1 (1.5)00.5No findings19 (13)6 (9.2)13 (15.5)0.4Sacroiliac Joint MRIn=148n= 65n= 83Any finding50 (33.5)27 (41.5)23 (27.4)0.07Structural findings31 (20.9)15 (23.1)16 (19.3)0.7Inflammatory findings11 (7.4)6 (9.2)5 (6.0)0.5Structural and Inflammatory findings7 (4.7)6 (9.2)1 (1.2)0.04No findings99 (67.8)38 (58.5)61 (73.5)0.08Figure 1.Patients with any reported finding in spine or sacroiliac joint magnetic resonance imaging.Colored: any finding. Striped: no findings.AcknowledgementsThe SHERPAS study has been conducted thanks to an unrestricted grants from Novartis.Disclosure of InterestsDiego Benavent Speakers bureau: Janssen, Roche, Abbvie, Galapagos., Grant/research support from: Novartis, Mar Tapia-Viñé: None declared, Daniel Bernabeu: None declared, Victor Muley: None declared, Chamaida Plasencia Speakers bureau: Pfizer, Abbvie, Lilly, Sandoz, Sanofi, Biogen, Roche, Novartis, Grant/research support from: Pfizer and Abbvie, Alejandro Balsa Speakers bureau: Pfizer, Abbvie, Lilly, Galapagos, BMS, Sandoz, Nordic Pharma, Gebro, Roche, Sanofi, UCB, Consultant of: Pfizer, Abbvie, Lilly, Galapagos, BMS, Nordic Pharma, Sanofi, UCB, Grant/research support from: Pfizer, Abbvie, BMS, Nordic Pharma, Gebro, Roche, UCB, Victoria Navarro-Compán Speakers bureau: AbbVie, Eli Lilly, Janssen, MSD, Novartis, Pfizer, UCB Pharma, Consultant of: AbbVie, Eli Lilly, MSD, Novartis, Pfizer, UCB Pharma, Grant/research support from: AbbVie and Novartis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call